Drugs / RN1101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06976437 | May 2025 → May 2027 expected | B-cell non-Hodgkin lymphoma, plasma cell myeloma | YANRU WANG | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06976437 ↗ |
| Action | Deplete | “ability of RN1101 to deplete CD19 or BCMA positive cells” NCT06976437 ↗ |
| Modality | Cell therapy | “RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA.” NCT06976437 ↗ |
| Route | Intravenous | “administered intravenously” NCT06976437 ↗ |
| Target | CD19 | “RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA.” NCT06976437 ↗ |